Loading
ST
Seelos Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Mehra Raj, was filed 01 Dec 2023.
Seelos Therapeutics, Inc.: what insiders have been doing
Seelos Therapeutics, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Seelos Therapeutics, Inc. The previous disclosure was published on 1 March 2024.
The full history, which starts in 2016, counts 9 purchases against no sales.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
69
Thresholds
n/a
Buy Volume
€7M
9 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -99.8%Entry US$250.88 · Close at T+365 US$0.42
- -99.8%Entry US$250.88 · Close at T+365 US$0.42
- +48.5%Entry US$2,474.88 · Close at T+365 US$3,675.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$1.9M
Gross profitUS$1.6M85% margin
EBITDA-US$37.8M-1990% margin
Net income-US$37.9M203.1% margin
Valuation
PER (trailing)0.0x
Beta4.25
Balance sheet & cash
Total debtUS$14.2M
Free Cash Flow-US$23.9M
Profitability & ownership
ROA-261.1%
% institutions0.0%
Last declaration on 1 March 2024
Declarations69 total
417 shares@ €1.01210.4% of flowCommon StockSEC:0001104659-24-030070:0
83,000 shares@ US$1.2075100.0% of flowCommon StockSEC:0001104659-23-122841:0
Canonical exit: 28 Feb 2024 (T+90)
75,757 shares@ US$1.3264.1% of flowCommon StockSEC:0001104659-23-122840:0
Canonical exit: 29 Feb 2024 (T+90)
12,500 shares@ €0.56996.1% of flowCommon StockSEC:0001104659-23-097765:0
12,500 shares@ €0.63336.8% of flowCommon StockSEC:0001104659-23-027915:0
16,000 shares@ US$0.6118100.0% of flowCommon StockSEC:0001136261-22-000249:0
Canonical exit: 30 Aug 2022 (T+90)
35,000 shares@ US$0.599100.0% of flowCommon StockSEC:0001136261-22-000247:0
Canonical exit: 24 Aug 2022 (T+90)
66,667 shares@ US$0.852635.9% of flowCommon StockSEC:0001136261-22-000159:0
Canonical exit: 29 Jun 2022 (T+90)
12,500 shares@ €0.8058100.0% of flowCommon StockSEC:0001136261-22-000155:0
133,333 shares@ US$0.75Common StockSEC:0001136261-20-000053:0
Canonical exit: 13 May 2020 (T+90)
3,081,546 sharesCommon StockSEC:0001136261-19-000011:0
32,705 shares@ US$0.2265Common StockSEC:0000899243-19-001840:0
44,810 shares@ US$0.2265Common StockSEC:0000899243-19-001841:0
17,290 shares@ US$0.306Common StockSEC:0000899243-18-029911:0
12,968 shares@ US$0.306100.0% of flowCommon StockSEC:0000899243-18-029913:0
81,775 sharesCommon StockSEC:0001017491-18-000083:0
43,225 shares@ US$0.33Common StockSEC:0001017491-18-000083:1
2,194 shares@ US$1.84Common StockSEC:0001017491-18-000005:0
7,679 shares@ US$1.8453.9% of flowCommon StockSEC:0001017491-18-000004:0
5,485 shares@ US$1.8453.9% of flowCommon StockSEC:0001017491-18-000006:0
14,093 shares@ US$1.5683.0% of flowCommon StockSEC:0001017491-17-000102:0
14,093 shares@ US$1.5646.1% of flowCommon StockSEC:0001017491-17-000101:0
18,790 shares@ US$1.5646.1% of flowCommon StockSEC:0001017491-17-000100:0
6,104 shares@ US$1.630.0% of flowCommon StockSEC:0001140361-17-034162:0
Canonical exit: 29 Nov 2017 (T+90)
100,000 sharesCommon StockSEC:0001017491-17-000086:0
25 of 69 declarations
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. It is listed on NASDAQ under the symbol SEEL.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
